Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Rashid S. Kazmi"'
Autor:
Rashid S. Kazmi, Bashir A. Lwaleed
Publikováno v:
Revista Brasileira de Hematologia e Hemoterapia, Vol 34, Iss 4, Pp 262-263 (2012)
Externí odkaz:
https://doaj.org/article/e92fa473f1c642acb0abf411cbb32a0a
Autor:
Sarah Bruty, Izabela James, Kordo Saeed, Lesley Heesom, Judith Effney, Savita Rangarajan, Josh Dmochowski, Ahilanandan Dushianthan, Rashid S. Kazmi, Jennifer Westwood, Nabil Abdul
Publikováno v:
Cureus
Background: the mortality of patients admitted to the intensive care unit (ICU) with COVID-19 remains significantly high. Severe COVID-19 pneumonia is characterised by refractory hypoxemia with significant shunting due to a combination of alveolar da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3baeba350479b79bcaf8f27e79bcc80c
https://eprints.soton.ac.uk/452055/
https://eprints.soton.ac.uk/452055/
Autor:
Herbert Gritsch, Michael Laffan, Rachel C Peck, Savita Rangarajan, Christopher Reilly-Stitt, Peter Turecek, Rashid S. Kazmi, Bruce Ewenstein, Ahilanandan Dushianthan, Wolfhard Erdlenbruch, Izabela James, Nikolaus B Binder, Gerald Schrenk, Andrew D Mumford, Nisha Jain, Bjorn Mellgard
Publikováno v:
Turecek, P L, Peck, R C, Rangarajan, S, Reilly-Stitt, C, Laffan, M A, Kazmi, R, James, I, Dushianthan, A, Schrenk, G, Gritsch, H, Ewenstein, B M, Mellgard, B, Erdlenbruch, W, Jain, N, Binder, N B & Mumford, A D 2021, ' Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19 ', Thrombosis Research, vol. 201, pp. 100-112 . https://doi.org/10.1016/j.thromres.2021.02.012
Thrombosis Research
Thrombosis Research
Thrombosis affecting the pulmonary and systemic vasculature is common during severe COVID-19 and causes adverse outcomes. Although thrombosis likely results from inflammatory activation of vascular cells, the mediators of thrombosis remain unconfirme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de441bca860c59a81bfa0e93a7aaeeca
https://hdl.handle.net/1983/e52272c0-958f-46b5-a39a-7ae5e2defcb1
https://hdl.handle.net/1983/e52272c0-958f-46b5-a39a-7ae5e2defcb1
Autor:
Emily Symington, Michiel Coppens, Michael Wang, Richard S. Lemons, Susan Lattimore, John Pasi, Doris Quon, Michael Recht, Adam S. Kotowski, Paul R. van der Valk, Rashid S. Kazmi, Giancarlo Castaman, Kathelijne Peerlinck, Peter Kampmann, Cedric Hermans, Nigel S. Key, Naghmana Bajma, Robert Klamroth, Steven W. Pipe, Jan Astermark, Robert Gut, Valerie Colletta, Rebecca Kruse-Jarres, Karina Meijer, Allison P. Wheeler, Eileen K. Sawyer, Frank W.G. Leebeek, Niamh M O'Connell, Guy Young, Wolfgang Miesbach, Stephanie Verweij, Miguel A. Escobar, Shelley E. Crary, Nathan Visweshwar, Annette von Drygalski, Esteban Gomez
Publikováno v:
Blood, 136. American Society of Hematology
Background: Etranacogene dezaparvovec is an investigational gene therapy for hemophilia B (HB) comprising an adeno-associated virus serotype 5 (AAV5) vector containing a codon-optimized Padua variant human factor IX (FIX) gene with a liver specific p
Autor:
Barbara A. Konkle, Stacy E. Croteau, John Pasi, Wolfgang Miesbach, Savita Rangarajan, Amy D. Shapiro, Marina Mihova, Rashid S. Kazmi, Charles R. M. Hay
Publikováno v:
Blood. 136:8-8
Hemophilia A (HA) arises from pathogenic variants in the F8 gene, affecting ~ 1/5000 males. Current factor replacement therapies have limitations, including treatment burden, kinetics (peaks/troughs), morbidity and mortality from breakthrough bleeds,
Publikováno v:
Seminars in Thrombosis and Hemostasis. 41:665-672
It is well established that inflammation and thrombosis are intricately linked processes, and there is increasing evidence of the importance of their roles in activated complement in the pathogenesis of thromboembolism. The two systems are activated
Autor:
Margaret V. Ragni, Michael Desmond Creagh, Akin Akinc, Inga Hegemann, Toshko Lissitchkov, Akshay Vaishnaw, K. John Pasi, Tim Mant, Pushkal Garg, Liana Gercheva-Kyuchukova, Margarita Timofeeva, Savita Rangarajan, Rashid S. Kazmi, Pencho Georgiev, Chang-Heok Soh, Steve Austin, David H. Bevan, Benny Sørensen, Charles R. M. Hay, Pratima Chowdary, Vasily Mamonov
Publikováno v:
The New England journal of medicine. 377(9)
BACKGROUND: Current hemophilia treatment involves frequent intravenous infusions of clotting factors, which is associated with variable hemostatic protection, a high treatment burden, and a risk of the development of inhibitory alloantibodies. Fitusi
Autor:
Rashid S. Kazmi, Bashir A. Lwaleed
Publikováno v:
British Journal of Clinical Pharmacology. 72:593-603
Conventional anticoagulants have proven efficacy in the management of thromboembolism. Their adverse effects and a narrow therapeutic window, necessitating regular need for monitoring, however, have long been an incentive for the development of safer
Autor:
Lara Carvalho Godoi, Bashir A. Lwaleed, Luci Maria Sant'Ana Dusse, Patrícia Nessralla Alpoim, Maria da Gloria Carvalho, Juliane Petterson, Rashid S. Kazmi
Publikováno v:
Seminars in Thrombosis and Hemostasis. 37:153-157
A plethora of evidence exists to show that endothelial perturbations underlie many of the clinical features of pre-eclampsia (P-EC), and consequently the markers signifying endothelial disturbance exhibit a rise in plasma. Among others, plasma thromb
Publikováno v:
Seminars in Thrombosis and Hemostasis. 37:131-136
Pronounced hemostatic changes occur during pregnancy, and the balance shifts markedly in favor of hypercoagulability. Although primarily a result of a marked rise in the levels of several procoagulants and a fall in some natural anticoagulants, plate